INVENTIVA (EPA:IVA) | Finanzwire

Basculer en Français

10107	Companies
207089	Keywords
137247	Articles
109772	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 11/20/2024 at 22:00, 1 year 4 months ago

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Inventiva reports total voting rights and shares as of November 4, 2024, in accordance with Article R. 22-10-23 of the French Commercial Code. The company is a clinical-stage biopharmaceutical with a focus on oral small molecule therapies

Shares Total Voting Rights Clinical-Stage Biopharmaceutical Inventiva MASH/NASH
PRESS RELEASE

published on 11/20/2024 at 22:00, 1 year 4 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Inventiva announces availability of preparatory documents for Combined General Meeting on December 11, 2024. Shareholders can participate in person or request documents electronically. Detailed resolutions and meeting information provided

Shareholders Resolutions Preparatory Documents Combined General Meeting Inventiva
BRIEF

published on 11/15/2024 at 22:05, 1 year 4 months ago

Inventiva Reveals Promising Phase 2 Study Results of Lanifibranor and Empagliflozin Combination

Phase 2 Study Clinical Trial Results Inventiva Lanifibranor MASH And T2D
PRESS RELEASE

published on 11/15/2024 at 22:00, 1 year 4 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva presents positive results from Phase 2 study on lanifibranor and empagliflozin combination therapy for MASH and T2D patients at AASLD The Liver Meeting® 2024

Inventiva MASH Lanifibranor Empagliflozin T2D
BRIEF

published on 10/30/2024 at 21:05, 1 year 4 months ago

Inventiva's Stock Rises Following Positive Update on Lanifibranor Trial

Inventiva MASH Lanifibranor NATiV3 Clinical Trial DMC Recommendation
PRESS RELEASE

published on 10/30/2024 at 21:00, 1 year 4 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Inventiva receives positive recommendation from fifth DMC review for lanifibranor in MASH Phase 3 trial, confirming good safety profile

Safety Data Inventiva MASH Lanifibranor Positive Recommendation
BRIEF

published on 10/23/2024 at 11:38, 1 year 5 months ago

Invus Public Equities exceeds thresholds at Inventiva

Voting Rights Capital Increase Crossing Thresholds Inventiva Invus Public Equities
BRIEF

published on 10/23/2024 at 11:36, 1 year 5 months ago

BVF Partners Crosses Thresholds in Inventiva's Capital

Voting Rights Capital Increase Crossing Thresholds Inventiva BVF Partners
BRIEF

published on 10/21/2024 at 14:35, 1 year 5 months ago

Inventiva presents an abstract at the Liver Meeting™ 2024

Clinical Trial Inventiva NASH Lanifibranor Liver Meeting™
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 5 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024

Inventiva MASH Lanifibranor LEGEND Phase 2 Empagliflozin

Accesswire

Published on 03/27/2026 at 15:35, 4 hours 10 minutes ago

SouthGobi Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Published on 03/27/2026 at 12:30, 7 hours 15 minutes ago

Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 7 hours 45 minutes ago

Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 12:00, 7 hours 45 minutes ago

Athena Gold Announces Share Consolidation
Published on 03/27/2026 at 11:00, 8 hours 45 minutes ago

RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation

View all ACCESSWIRE

EQS Group

Published on 03/27/2026 at 19:30, 15 minutes ago

Turning Potential into Reality: Future 500 Ignites Scale-Up Momentum in Europe
Published on 03/27/2026 at 19:30, 15 minutes ago

FONDAZIONE MAIRE PRESENTED IN BERLIN THE "CLIMATE GOALS" STUDY IN THE FRAMEWORK OF MAIRE EUROPEAN STRATEGY LEVERAGING ON GERMANY
Published on 03/27/2026 at 19:25, 20 minutes ago

Boris Becker's 1989 U.S. Open Champion Trophy Up For Auction, $350,000+ Expected
Published on 03/27/2026 at 18:25, 1 hour 20 minutes ago

Thieves Make a Break For It as 12 Tonnes of KITKAT Go Missing
Published on 03/27/2026 at 18:20, 1 hour 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 03/27/2026 at 19:06, 39 minutes ago

Mersen: Disclosure of trading own shares
Published on 03/27/2026 at 18:52, 53 minutes ago

Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 1 hour 5 minutes ago

2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 1 hour 52 minutes ago

Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 2 hours ago

PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025

View all LES ECHOS COMFI WIRE